Check out your Company Bowl for anonymous work chats.
Andrew Trister, Verily Chief Medical and Scientific Officer, will be speaking at the PMWC Precision Medicine World Conference on February 6 during the session, AI-Powered RWE: Accelerating Drug Development and Post-Market Applications. He’ll join fellow experts Michelle Chen, Jun Jeon, Dan Riskin and moderator Erik Reinertsen to explore AI-driven drug development.
Feb. 6 - Track 2: AI Models for RWE/D Applications Track - PMWC Precision Medicine World Conference
Health data is precious. It's personal. It needs to be protected at the highest level. As a company who partners with life sciences, health plans, employers, and consumers, we take health data protection very seriously. Thank you to the security experts at Verily who make sure the health data we manage is protected, governed, and safe.
Data Security and Trust | Verily
The eye is the window into human health. Superior Health and Verily are partnering to bring advanced retinal screenings to the Rio Grande Valley, a region with one of the highest diabetes rates in the US. Learn how this initiative is transforming eye care access for this underserved community in the next episode of our N of 1 series, Eye on the Future.
Retinal Screenings | Diabetes Care | Superior Health & Verily
Verily Clinical Pharmacist, Denise Mackenzie, has dedicated her career to creating relationships with her patients, helping them overcome personal barriers to better medication outcomes, and drawing from her own experience managing diabetes. She serves as a partner and bridge, connecting virtual, chronic care members to the tools, resources, information, and support they need to lead healthier lives. Learn about her passion for providing more personal, precise care.
Meet Denise MacKenzie, Verily chronic care pharmacist
This week at the JPM Healthcare Conference, our CEO Stephen Gillett presented Verily’s vision, strategy, and business updates. ➡ At the heart, Verily is a health tech company that brings together the power of AI, our data platform technology, and a deep understanding of data at scale to build solutions that have a meaningful impact on precision health. ➡ 97% of all healthcare data is not being used to inform decisions. Verily’s goal is to harmonize and activate this data at scale, so that customers can generate insights to make healthcare more personal and precise. ➡ The core of Verily’s DNA is our understanding of AI and large datasets, and how they can be applied to deliver more precise healthcare solutions for our customers and patient populations.
This week at the JPM Healthcare Conference, our CEO Stephen Gillett presented Verily’s vision, strategy, and business updates. ➡ At the heart, Verily is a health tech company that brings together the power of AI, our data platform technology, and a deep understanding of data at scale to build solutions that have a meaningful impact on precision health. ➡ 97% of all healthcare data is not being used to inform decisions. Verily’s goal is to harmonize and activate this data at scale, so that customers can generate insights to make healthcare more personal and precise. ➡ The core of Verily’s DNA is our understanding of AI and large datasets, and how they can be applied to deliver more precise healthcare solutions for our customers and patient populations.
Verily’s Andrew Trister delivered the keynote address to a full house at the H7 JPM Investment Forum & Demo Day. He explored the evolution of AI tools in medicine, their historical applications, and the transformative potential they hold for the healthcare landscape in 2025 and beyond.
Verily’s Andrew Trister delivered the keynote address to a full house at the H7 JPM Investment Forum & Demo Day. He explored the evolution of AI tools in medicine, their historical applications, and the transformative potential they hold for the healthcare landscape in 2025 and beyond.
“By incorporating the existing data available within the health system with data that is person-generated (through wearables, or other types of data) we will have an unprecedented approach to building proactive [AI] agents that can help a person better understand their own health and disease,” said Andrew Trister, Verily Chief Medical and Scientific Officer. Read more of his 2025 predictions for advancements in AI, which emphasize potential benefits in oncology and chronic disease management.
Medtech 2025 Expert AI Predictions: 'Biggest Leap Leveraging AI In Oncology,' Says Verily's Andrew Trister; Multimodal Integration, Use Of AI Agents
With data from wastewater surveillance, public health officials can understand what pathogens are present and make informed decisions about how to support communities. Watch how Verily works with wastewater epidemiologists and treatment facilities to turn water into wisdom in the Las Vegas Valley.
A Watershed Moment
What will 2025 bring for employers? Verily’s Chief Clinical Officer and Head of Health Equity Vindell Washington sat down with FierceHealthcare to discuss challenges and opportunities for employers in the year ahead, including the need for more comprehensive chronic condition management programs.
https://www.fiercehealthcare.com/payers/2025-outlook-employers-face-yet-another-year-healthcare-cost-increases
We’re thrilled to see Verily CEO Stephen Gillett be named to D CEO's Dallas 500, a list of the 500 most significant and influential leaders in North Texas. Verily is proud to be part of the growing DFW healthcare and tech ecosystem and we look forward to our continued contributions in the years ahead. Congratulations to Stephen and all the other honorees!
Dallas 500